Chen, Ina Mathews-Greiner, Lesley Li, Dandan Abisoye-Ogunniyan, Abisola Ray, Satyajit Bian, Yansong Shukla, Vivek Zhang, Xiaohu Guha, Raj Thomas, Craig Gryder, Berkley Zacharia, Athina Beane, Joal Ravichandran, Sarangan Ferrer, Marc Rudloff, Udo MOESM7 of Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer Additional file 7: Figure S5. Selective pharmacological vulnerabilities of c.1380delA SB.mhdgc-1 versus SB.msgc-1 gastric cancer cells identified by comparative qHTS screening with the MIPE Oncology 4.0 library. A, Bubble diagram of drug phenotypes by compound class of SB.mhdgc-1 versus SB.msgc-1 cells depicting class activities (number of compounds per drug class) measured by maximum response (max response SB.mhdgc-1 / max response SB.msgc-1). B, Bubble diagram comparing drug activities measured by potency (logAC50SB.mhdgc-1 versus logAC50SB.msgc-1). Hereditary diffuse gastric cancer (HDGC);High throughput drug screening;Therapeutic leads;c.1380delA CDH1 gastric cancer cells;Differential gene expression profiling 2017-05-01
    https://springernature.figshare.com/articles/presentation/MOESM7_of_Transcriptomic_profiling_and_quantitative_high-throughput_qHTS_drug_screening_of_CDH1_deficient_hereditary_diffuse_gastric_cancer_HDGC_cells_identify_treatment_leads_for_familial_gastric_cancer/4959392
10.6084/m9.figshare.c.3768611_D7.v1